Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-02-03 7:04 pm Sale | 13D | Galera Therapeutics, Inc. GRTX | Sofinnova Venture Partners IX L.P. | 3,083,712 10.8% | -1,098 (-0.04%) | View |
| 2021-03-04 06:17 am Sale | 13D | Entasis Therapeutics Holdings Inc. ETTX | Sofinnova Venture Partners IX L.P. | 0 0% | -1,180,178 (Position Closed) | View |
| 2020-08-19 11:58 am Purchase | 13D | Checkmate Pharmaceuticals, Inc. CMPI | Sofinnova Venture Partners IX L.P. | 3,606,707 16.8% | 3,606,707 (New Position) | View |
| 2020-06-05 4:48 pm Sale | 13D | Iterum Therapeutics plc ITRM | Sofinnova Venture Partners IX L.P. | 6,154 0% | -1,726,514 (-99.64%) | View |
| 2020-04-27 1:04 pm Sale | 13D | Merus N.V. MRUS | Sofinnova Venture Partners IX L.P. | 1,311,039 4.5% | -439,060 (-25.09%) | View |
| 2020-02-13 1:26 pm Unchanged | 13G | Chiasma, Inc. CHMA | Sofinnova Venture Partners IX L.P. | 1,767,102 4.2% | 0 (Unchanged) | View |
| 2020-01-24 9:51 pm Purchase | 13D | Iterum Therapeutics plc ITRM | Sofinnova Venture Partners IX L.P. | 1,732,668 11.6% | 6,154 (+0.36%) | View |
| 2019-11-21 8:05 pm Purchase | 13D | NextCure, Inc. NXTC | Sofinnova Venture Partners IX L.P. | 2,671,856 10% | 150,000 (+5.95%) | View |
| 2019-11-19 8:48 pm Purchase | 13D | Galera Therapeutics, Inc. GRTX | Sofinnova Venture Partners IX L.P. | 3,084,810 12.7% | 3,084,810 (New Position) | View |
| 2019-05-16 8:46 pm Purchase | 13D | NextCure, Inc. NXTC | Sofinnova Venture Partners IX L.P. | 2,521,856 11.1% | 2,521,856 (New Position) | View |
| 2019-03-27 6:03 pm Sale | 13D | PDS Biotechnology Corp EDGE | Sofinnova Venture Partners IX L.P. | 142,635 2.7% | -2,710,076 (-95.00%) | View |
| 2019-02-11 8:02 pm Sale | 13D | Ascendis Pharma A/S ASND | Sofinnova Venture Partners IX L.P. | 2,044,001 4.9% | -488,054 (-19.28%) | View |
| 2019-02-11 7:43 pm Sale | 13D | aTyr Pharma, Inc. LIFE | Sofinnova Venture Partners IX L.P. | 0 0% | -1,694,528 (Position Closed) | View |
| 2019-01-11 3:54 pm Purchase | 13D | Ascendis Pharma A/S ASND | Sofinnova Venture Partners IX L.P. | 2,532,055 6% | 293,791 (+13.13%) | View |